Search
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].
Gemeprost
go.drugbank.com/drugs/DB08964ApprovedWithdrawnIt is not FDA-approved but available in Japan marketed as Preglandin.
Tideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawn[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Celecoxib
go.drugbank.com/drugs/DB00482ApprovedInvestigational[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … , sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst other cell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by
Guanfacine
go.drugbank.com/drugs/DB01018ApprovedInvestigationalGuanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release
Mepyramine
go.drugbank.com/drugs/DB06691ApprovedVet approvedIt has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
Dorzolamide
go.drugbank.com/drugs/DB00869ApprovedInvestigational[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart
Gadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigational[A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151] … [A263146] Since gadoxetate uptake is mediated by organic anion-transporting polypeptides (OATPs) and liver tumor cells lack OATPs, liver tumors show a lack of contrast of enhancement and therefore heightening